Cargando…

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic landscape of haematological malignancies. However, resistance and relapse remain prominent limitations, and they are related to the limited persistence and efficacy of CAR T cells, downregulation or loss of tumour anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Xinyi, Wang, Yazhuo, Zou, Zhengbang, Yang, Yufei, Wang, Xinyu, Xin, Xin, Tu, Sanfang, Li, Yuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460961/ https://www.ncbi.nlm.nih.gov/pubmed/36091028 http://dx.doi.org/10.3389/fimmu.2022.954235

Ejemplares similares

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
por: Guo, Zhenling, et al.
Publicado: (2021)

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021)

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
por: Zhou, Xuan, et al.
Publicado: (2020)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
por: Zheng, Diwei, et al.
Publicado: (2022)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
por: Sun, Wei, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
por: Xiao, Bu-Fan, et al.
Publicado: (2021)

New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center
por: Kong, Danqing, et al.
Publicado: (2023)

Chimeric antigen receptor T cells applied to solid tumors
por: Zhou, Zhongguo, et al.
Publicado: (2022)

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis
por: Grigor, Emma J M, et al.
Publicado: (2017)

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection
por: Niu, Anna, et al.
Publicado: (2023)

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013)

Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology
por: Jin, Xin, et al.
Publicado: (2021)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
por: Kosti, Paris, et al.
Publicado: (2018)

Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
por: Kranz, Emiko, et al.
Publicado: (2022)

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
por: Thornton, Christopher, et al.
Publicado: (2012)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Cytomegalovirus in Haematological Tumours
por: Alonso-Álvarez, Sara, et al.
Publicado: (2021)

A Novel Strategy to Identify Haematology Patients at High Risk of Developing Aspergillosis
por: Griffiths, James S., et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
por: Hermanson, David L., et al.
Publicado: (2015)

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
por: Mehta, Rohtesh S., et al.
Publicado: (2018)

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing
por: Liu, Jie, et al.
Publicado: (2019)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022)

Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes
por: Nanjireddy, Priyanka Maridhi, et al.
Publicado: (2023)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
por: Xie, Danni, et al.
Publicado: (2022)

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
por: Zhang, Chengcheng, et al.
Publicado: (2023)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4slbj6l57g2d23ofn6mebbp38c